Today, Insmed Inc. (INSM) Receives $20.75 Average Target Price from Brokerages

Today, Insmed Inc. (INSM) Receives $20.75 Average Target Price from Brokerages

Shares of Insmed Inc. (NASDAQ:INSM) have been assigned a consensus recommendation of “Buy” from the seven brokerages that are presently covering the firm. Two research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $20.75.

A number of research analysts have issued reports on the company. Zacks Investment Research upgraded Insmed from a “sell” rating to a “hold” rating in a research note on Wednesday, August 17th. Piper Jaffray Cos. set a $24.00 price objective on Insmed and gave the company a “buy” rating in a research note on Sunday, August 21st. Finally, HC Wainwright reiterated a “buy” rating on shares of Insmed in a research note on Friday, November 4th.

In other Insmed news, CFO Andrew T. Drechsler sold 45,000 shares of Insmed stock in a transaction on Monday, November 14th. The stock was sold at an average price of $14.67, for a total value of $660,150.00. Following the completion of the sale, the chief financial officer now owns 20,000 shares of the company’s stock, valued at approximately $293,400. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Orlov S. Nicole Schaeffer sold 68,774 shares of Insmed stock in a transaction on Wednesday, November 9th. The stock was sold at an average price of $11.95, for a total value of $821,849.30. Following the completion of the sale, the senior vice president now directly owns 37,500 shares of the company’s stock, valued at approximately $448,125. The disclosure for this sale can be found here. 4.03% of the stock is owned by company insiders.

Hedge funds have recently bought and sold shares of the company. Emerald Acquisition Ltd. acquired a new stake in Insmed during the third quarter worth approximately $121,000. Pacad Investment Ltd. purchased a new stake in shares of Insmed during the second quarter valued at approximately $124,000. TFS Capital LLC purchased a new stake in shares of Insmed during the second quarter valued at approximately $137,000. Princeton Alpha Management LP raised its stake in shares of Insmed by 56.0% in the third quarter. Princeton Alpha Management LP now owns 15,713 shares of the biopharmaceutical company’s stock valued at $228,000 after buying an additional 5,638 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Insmed during the second quarter valued at approximately $278,000. 91.99% of the stock is owned by institutional investors and hedge funds.

Insmed (NASDAQ:INSM) opened at 14.57 on Tuesday. The stock’s 50 day moving average price is $13.81 and its 200-day moving average price is $12.44. Insmed has a 12 month low of $9.02 and a 12 month high of $19.30. The stock’s market cap is $901.55 million.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.61) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.59) by $0.02. Analysts anticipate that Insmed will post ($2.57) EPS for the current fiscal year.

Related posts

Leave a Comment